Introduction
============

Atherosclerosis is a common pathological etiology of various cardiovascular diseases ([@B10]). The pathogenesis of atherosclerosis is quite complex with various theories and hypotheses. It is well accepted that vascular endothelial dysfunction is the initial event in atherosclerosis ([@B5]; [@B20]). Oxidized low-density lipoprotein (oxLDL) is an important pathogenic factor associated with endothelial dysfunction in atherosclerosis ([@B30]). OxLDL stimulates endothelial cells to secrete a variety of adhesion molecules and chemotactic factors and promotes the adhesion of monocytes to endothelial cells, leading to the migration to the intima ([@B6]; [@B18]). The monocytes in the intima differentiate into macrophages, which phagocytize excess lipids, finally leading to the formation of foam cells ([@B39]; [@B21]).

Endogenous hydrogen sulfide (H~2~S) is the third gaseous molecule following nitric oxide (NO) and carbon monoxide (CO). It has been widely involved in various physiological and pathological processes ([@B14]). In the cardiovascular system, H~2~S is physiologically generated by cystathionine-γ-lyase (CSE) ([@B50]; [@B17]). It has been found that the defects of endogenous CSE/H~2~S system promote the development of atherosclerosis ([@B44]; [@B26]), whereas up-regulation of endogenous CSE/H~2~S pathway suppresses atherosclerosis ([@B4]). The protection of H~2~S on endothelial functions is the main mechanism underlying H~2~S inhibition of atherosclerosis ([@B1]). To date, the CSE/H~2~S system has already become an important regulator for atherosclerosis therapy ([@B27]; [@B47]). Exploring the mechanisms regulating the CSE/H~2~S pathway and search for potential targets to regulate this system are important for protecting the function of vascular endothelial cells and inhibiting the progression of atherosclerosis.

More recently, epigenetics has been increasingly appreciated to play a key role in atherosclerosis through altering gene expression and cell functions ([@B3]; [@B25]; [@B2]). DNA methylation, one of the epigenetic modifications, predominantly occurs in CpG dinucleotides to induce chromatin structure changes which are often associated with gene repression ([@B29]). Ten-eleven translocation-2 (TET2) protein is a DNA demethylase that oxidizes 5-methylcytosine (5mC) to generate 5-hydroxymethylcytosine (5hmC) and promote DNA demethylation and activation of gene expression ([@B42]; [@B24]). It was reported that the expression of TET2 and 5-hmC in human atherosclerotic plaques is significantly lower than that in normal blood vessels ([@B24]). TET2 levels are inversely correlated with the severity of atherosclerosis ([@B24]). Our previous studies have found that TET2 inhibits atherosclerosis in ApoE knockout mice ([@B36]). We also found that TET2 is involved in regulation of endothelial cell functions under low shear stress ([@B48]). However, the relationship between TET2 and the CSE/H~2~S system and its role in endothelial dysfunction remain unclear.

Here, we first examined the intracellular TET2 expression and the change of CSE/H~2~S system in the oxLDL-treated human umbilical vascular endothelial cells (HUVECs). Then, we further determined whether TET2 regulates oxLDL-induced dysfunction of HUVECs via the CSE/H~2~S system, and investigated the underlying mechanism in this progress in term of DNA demethylation.

Materials and Methods {#s1}
=====================

Cell Culture and Treatment
--------------------------

Human umbilical vascular endothelial cells were purchased from the China Center for Type Culture Collection and cultured as previously described ([@B48]). Briefly, HUVECs were cultured at 37°C with 5% CO~2~ in Dulbecco's Modified Eagle's medium (DMEM, GIBCO) containing 10% FBS. Cells were treated with different concentrations of oxLDL and also treated for different time periods.

Cell Transfection
-----------------

Human umbilical vascular endothelial cells (4 × 10^5^ cells per well) were seeded in a six-well plate and then transfected with the TET2 plasmid for overexpression (OriGene Technologies Inc.) or TET2 shRNA (OriGene Technologies Inc.) using Lipofectamine^®^2000 (Invitrogen) in accordance with the manufacturer's instruction. After 6 h, the transfection mixture was replaced with fresh growth medium. Co-transfection with TET2 overexpression plasmid and CSE siRNA (Guangzhou RiboBio Co., Ltd.) in HUVECs was carried out according to siRNA plasmid co-transfection protocol with Lipofectamine^®^2000. Subsequent experiments with transfected cells were performed after transfection for 24 h.

Detection of H~2~S Contents in Cells
------------------------------------

Hydrogen sulfide generation in cultured HUVECs was examined as previously described ([@B46]). Briefly, filtration membranes were pretreated by zinc acetate solution and pasted on the inside of the plate lid. Cells were then cultured for 8 h. H~2~S released from HUVECs was trapped by zinc acetate in the filtration membrane to generate ZnS deposition. Then the ZnS deposition was measured by methylene blue assay. The absorbance of the resulting solution was measured with a spectrometer at a wavelength of 655 nm. The H~2~S concentration in the solution was calculated according to the calibration curve of the standard H~2~S solution.

To image the intracellular H~2~S levels, a highly selective and sensitive H~2~S probe-N3 obtained from Dr. J. L. Wang (Hunan University, China) was used. H~2~S Probe-N3 was added in the medium as the final concentration of 20 μmol/L. After 30 min incubation, cells were washed with PBS three times to remove the excess probe. Fluorescence images were taken with a fluorescence microscope (NikenE600, Tokyo).

Adhesion Assay
--------------

Upon completion of indicated transfection, HUVECs were incubated with 75 μg/ml oxLDL for 24 h. Then, 1 × 10^5^ THP-1 cells were seeded onto confluent HUVECs, followed by 30 min incubation. Non-adherent THP-1 cells were removed by washing with PBS. The number of adhered THP-1 cells to HUVECs was observed and counted with an Olympus optical microscope system. The results were expressed as the mean number of cells per optical field at Scale bar = 50 μm.

Immunostaining
--------------

Cells were fixed with 4% paraformaldehyde for 10 min, washed thee with PBS, and treated with 0.1% Triton X-100 for 10 min. Then cells were blocked in 10% normal goat serum for 30 min. The cell samples were incubated with primary antibodies for NF-κB p65 (1:200, Proteintech), 5-hmC (1:200, Epigentek) at 4°C overnight. After washed with PBS, cells were incubated with Cy3-conjugated affinipure goat anti-Rabbit IgG (1:100, Proteintech) or anti-Mouse IgG (1:100, Proteintech). The nuclei were counterstained with 4′,6-Diamidino-2-Phenylindole (DAPI). Immunofluorescence images were obtained using a Nikon E600 fluorescence microscope.

Real-Time PCR
-------------

Total RNA was isolated using Trizol reagent (Shanghai Pu Fei Biotechnology Co., Ltd.) following the manufacturer's instructions. The cDNA was prepared with the First-Strand Synthesis System (Promega), and then real-time PCR was carried out with the SYBR green PCR Master Mix (Applied Biosystems). Quantitative evaluation was analyzed using the Ct method. GAPDH expression was used as the internal control. The primer sequences were listed in Supplementary Table [S1](#SM2){ref-type="supplementary-material"}.

Western Blotting Analysis
-------------------------

Cells were washed twice with chilled PBS and lysed with radioimmunoprecipitation assay buffer (RIPA buffer) for protein extraction as previously described. The primary antibodies used include GAPDH (1:1000, Hangzhou Goodhere Biotechnology Co., Ltd.), TET2 (1:1000, Proteintech), CSE (1:1000, Proteintech), ICAM-1 (1:1000, Proteintech), VCAM-1 (1:500, Santa Cruz), IκBα (1:1000, Proteintech), NF-κB p65 (1:1000, Proteintech), and Histone H3 (1:5000, Abcam). The chemiluminescence immunoblotting detection system (Shanghai Tanon, China) was used to analyze immunoreactive protein bands.

DNA Methylation Analysis
------------------------

DNA methylation analysis was carried out as previously described. Briefly, Genomic DNA Clean & Concentrator^TM^ Kit (D4011, Zymo Research) was used to extract genomic DNA from HUVECs. EZ DNA Methylation-Direct^TM^ Kit (D5020, Zymo Research) was applied to complete bisulfite conversion of genomic DNA in accordance with the manufacturer's protocols. Bisulfite sequencing primers were designed by MethPrimer software. Upon ligation, the purified bisulfite PCR product of samples was cloned into the pBLUE-T vector system \[ZC204, ComingTech InnoBIO (Beijing) Co., Ltd.\]. After bacterial transformation, at least five bacterial colonies on the dish plates were selected and sent for direct sequencing in GenomeLab^TM^ GeXP Genetic Analysis System (Beckman Coulter). The sequencing data were analyzed by the BiQ Analyzer software. The primer sequences were for BSP listed in Supplementary Table [S1](#SM2){ref-type="supplementary-material"}.

Statistical Analysis
--------------------

Data were presented as mean ± SD. Statistical analyses were performed with the GraphPad Prism 5.0 Software. Differences between groups were analyzed with one-way analysis of variance (ANOVA). Differences were considered statistically significant when *p* \< 0.05.

Results
=======

OxLDL Downregulates TET2 Expression and the CSE/H~2~S System in HUVECs
----------------------------------------------------------------------

Human umbilical vascular endothelial cells were incubated with different concentrations of oxLDL and treated for different time periods. OxLDL treatment of HUVECs resulted in an obvious decrease in TET2 mRNA and protein expression. The decrease in response to oxLDL treatment was in both concentration- and time-dependent manners (**Figures [1A](#F1){ref-type="fig"}--[D](#F1){ref-type="fig"}**). The levels of CSE mRNA and protein also were downregulated in a concentration- and time-dependent fashion by oxLDL in HUVECs (**Figures [1E](#F1){ref-type="fig"}--[H](#F1){ref-type="fig"}**). In line with the change of CSE expression, H~2~S production rate and level were significantly reduced in HUVECs treated with oxLDL as shown in **Figures [1I](#F1){ref-type="fig"}--[K](#F1){ref-type="fig"}**. Therefore, the above results revealed that the downregulation of the CSE/H~2~S system in oxLDL-stimulated HUVECs was consistent with the alteration of TET2 expression.

![Effect of oxLDL on TET2 expression and the CSE/H~2~S system in HUVECs. **(A--D)** OxLDL reduced TET2 mRNA and protein expression in HUVECs at the concentration-dependent fashion (0, 25, 50, 75, and 100 μg/ml). 75 μg/ml oxLDL decreased TET2 mRNA and protein expression in HUVECs at the time-dependent manner (0, 12, 24, and 48 h). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. 0 μg/ml oxLDL group **(A,B)** or vs. 0 h group **(C,D)**. **(E--H)** OxLDL reduced CSE mRNA and protein expression in HUVECs at the concentration-dependent fashion (0, 25, 50, 75, and 100 μg/ml) and 75 μg/ml oxLDL decreased CSE mRNA and protein expression in HUVECs at the time-dependent fashion (0, 12, 24, and 48 h). ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. 0 μg/ml oxLDL group **(E,F)** or vs. 0 h group **(G,H)**. **(I,J)** The effects of increasing concentrations of oxLDL on the H~2~S production rates in cells and the effects of 75 μg/ml oxLDL on H~2~S production rates in cells over time. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. 0 μg/ml oxLDL group **(I)** or vs. 0 h group **(J)**. **(K)** Detection of intracellular H~2~S levels in HUVECs with or without 75 μg/ml oxLDL treatment for 24 h using H~2~S-specific fluorescent probes. Representative fluorescent images were taken using a fluorescent microscope. Scale bar = 20 μm. All results are expressed as the mean ± SD of three independent experiments.](fphar-08-00486-g001){#F1}

Since treatment with 75 μg/ml oxLDL for 24 h resulted in a consistent and predictable response in terms of TET2 expression and the CSE/H~2~S system change in HUVECs, the subsequent experiments were performed with this concentration of oxLDL and treatment time.

TET2 Improves oxLDL-Induced Dysfunction of HUVECs
-------------------------------------------------

To explore the role of TET2 in oxLDL-induced dysfunction of HUVECs, we chose oxLDL-treated HUVECs as a cell model and transduced the cells with TET2 overexpression plasmid or TET2 shRNA plasmid for TET2 overexpression or silencing, respectively (**Figure [2A](#F2){ref-type="fig"}**). Then, we first investigated the effect of TET2 on the adhesion of THP-1 cells to oxLDL-activated HUVECs, which indicates the function of HUVECs. As shown in **Figures [2B,C](#F2){ref-type="fig"}**, the adhesion of THP-1 cells to oxLDL-activated HUVECs was attenuated by TET2 overexpression. However, TET2 silencing markedly increased adhesion of monocytes to HUVECs treated with oxLDL.

![Effects of TET2 on the oxLDL-induced dysfunction of HUVECs. **(A)** The effects of TET2 overexpression and shRNA plasmids on TET2 protein expression in HUVECs. **(B,C)** HUVECs were transduced with TET2 overexpression plasmid or TET2 shRNA plasmid, then treated with 75 μg/ml oxLDL for 24 h. THP-1 cells were seeded onto HUVECs and co-cultured for 30 min. After washing the non-adherent cells, adherent cells were detected and counted under a light microscope. Representative light microscopic pictures of THP-1 cell adhesion to oxLDL-activated HUVECs **(B)** and quantitative analysis of adhesion results **(C)**. Data are the mean ± SEM of results from at least three independent experiments, each performed in duplicate. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control (treated with oxLDL alone) group. **(D--G)** The mRNA and protein levels of ICAM-1 and VCAM-1 in oxLDL-treated HUVECs with TET2 overexpression or TET2 silencing were determined by real-time PCR and western blot analyses. All results are expressed as the mean ± SD of three independent experiments, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control (treated with oxLDL alone) group. All results are expressed as the mean ± SD of three independent experiments, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control group.](fphar-08-00486-g002){#F2}

ICAM-1 and VCAM-1 are considered as the key adhesion molecules that are induced by oxLDL in HUVECs, which then promote the adhesion of monocytes to HUVECs ([@B8]). The results of real-time PCR and western blot analyses demonstrated that ICAM-1 and VCAM-1 mRNA and protein expressions were decreased in oxLDL-treated HUVECs with TET2 overexpression and increased in oxLDL-treated HUVECs with TET2 silencing compared with those in cells treated with oxLDL alone (**Figures [2D](#F2){ref-type="fig"}--[G](#F2){ref-type="fig"}**). These data indicate that TET2 results in an improvement of endothelial dysfunction induced by oxLDL.

TET2 Upregulates the CSE/H~2~S System in oxLDL-Treated HUVECs
-------------------------------------------------------------

Next, the experiments were carried out to investigate the impact of TET2 on the CSE/H~2~S system in oxLDL-treated HUVECs. TET2 overexpression resulted in a remarked increase in the mRNA and protein mass of CSE in HUVECs (**Figures [3A,B](#F3){ref-type="fig"}**) along with an enhanced H~2~S production rate and an increased intracellular H~2~S level (**Figures [3C,D](#F3){ref-type="fig"}**). In line with these findings, silencing of TET2 led to the suppression of CSE mRNA and protein expression, resulting in low H~2~S production rate and intracellular H~2~S level in oxLDL-treated HUVECs (**Figure [3](#F3){ref-type="fig"}**).

![Effects of TET2 on the CSE/H~2~S system in oxLDL-induced dysfunction of HUVECs. HUVECs were transfected with or without TET2 overexpression plasmid or TET2 shRNA plasmid in the presence of oxLDL for 24 h. The expression of CSE mRNA **(A)** and protein **(B)** was examined via real-time PCR and western blot analyses in cells. **(C)** The H~2~S production rates in each group of cells were determined as described in "Materials and Methods" section. **(D)** Representative fluorescent images of intracellular H~2~S levels in each group of cells using H~2~S-specific fluorescent probes. Scale bar = 20 μm. All results are expressed as the mean ± SD of three independent experiment. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control group.](fphar-08-00486-g003){#F3}

TET2 Inhibits NF-κB Activation in oxLDL-Treated HUVECs
------------------------------------------------------

NF-κB, a major target molecule at the downstream of H~2~S, is the key regulator of ICAM-1 and VCAM-1 expression. So, we examined the modulation of NF-κB activation by TET2 overexpression plasmid and TET2 shRNA plasmid in oxLDL-treated HUVECs. Transfection of TET2 overexpression plasmid to cells led to an inhibition of IkBα degradation and NF-κB p65 nuclear translocation, whereas transfection with TET2 shRNA plasmid significantly promoted IkBα degradation and NF-κB p65 nuclear translocation in oxLDL-treated HUVECs (**Figure [4](#F4){ref-type="fig"}**). Thus, these data point to an inhibitory role of TET2 in NF-κB activation in oxLDL-treated HUVECs.

![Effects of TET2 on NF-κB activation in oxLDL-induced dysfunction of HUVECs. HUVECs were transfected with or without TET2 overexpression plasmid or TET2 shRNA plasmid in the presence of oxLDL for 24 h. The levels of IkBα protein **(A)** and nuclear NF-κB p65 protein **(B)**, respectively, were evaluated by western blot analysis in each group of cells. All results are expressed as the mean ± SD of three independent experiment. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. control group. **(C)** Distribution of NF-κB p65 protein expression was detected by immunostaining in each group of cells. NF-κB p65 positive staining is red. NF-κB p65 accumulation in the nuclei of the cells shows pink. DAPI staining is blue. Scale bar = 20 μm.](fphar-08-00486-g004){#F4}

The CSE/H~2~S System Mediates the Improvement Effect of TET2 on oxLDL-Induced Dysfunction of HUVECs
---------------------------------------------------------------------------------------------------

Subsequently, we determined whether the CSE/H~2~S system mediates the improvement effect of TET2 on oxLDL-induced dysfunction of HUVECs. To do so, we interfered the CSE/H~2~S system using chemically synthesized CSE siRNA in oxLDL-treated HUVECs with TET2 overexpression. As expected, CSE siRNA suppressed CSE protein expression (**Supplementary Figure [S1A](#SM1){ref-type="supplementary-material"}**) and reduced H~2~S production rate (**Supplementary Figure [S1B](#SM1){ref-type="supplementary-material"}**) and intracellular H~2~S level in cells (**Supplementary Figure [S1C](#SM1){ref-type="supplementary-material"}**). As shown in **Figures [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**, CSE siRNA ameliorated the suppression effect of TET2 overexpression on the adhesion of THP-1 cells to oxLDL-activated HUVECs and the levels of ICAM-1 and VCAM-1 protein in cells. In addition, the inhibition effect of TET2 overexpression on IkBα degradation and NF-κBp65 nuclear translocation was blocked by CSE siRNA in oxLDL-treated HUVECs (**Figures [5E](#F5){ref-type="fig"}--[G](#F5){ref-type="fig"}**). Collectively, these data demonstrated that the CSE/H~2~S system mediates the improvement effect of TET2 on the oxLDL-induced dysfunction of HUVECs.

![Effects of the CSE/H~2~S system on the TET2-induced improvement of oxLDL-treated dysfunction of HUVECs. HUVECs were transfected with or without TET2 overexpression plasmid or TET2 overexpression plasmid + CSE siRNA in the presence of oxLDL for 24 h. **(A,B)** Representative microscopic images of the adhesion of THP-1 cells to HUVECs **(A)** and quantitative analysis of adhesion results. Data are the mean ± SEM of results from at least three independent experiments. **(B).** The ICAM-1 **(C)** and VCAM-1 **(D)** proteins were evaluated by western blot analysis in each group of cells. The levels of IkBα protein **(E)** and nuclear NF-κB p65 protein **(F)**, respectively, were examined by western blot analysis in each group of cells. **(G)** Distribution of NF-κB p65 protein expression was detected by immunostaining in each group of cells. NF-κB p65 positive staining is red. NF-κB p65 accumulation in the nuclei of the cells shows pink. DAPI staining is blue. Scale bar = 20 μm. All results are expressed as the mean ± SD of three independent experiments. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. oxLDL-treated alone group. ^\#\#^*P* \< 0.01 vs. TET2 overexpression plasmid-treated group.](fphar-08-00486-g005){#F5}

TET2 Induces Demethylation of CSE Promoter in oxLDL-Treated HUVECs
------------------------------------------------------------------

To elucidate the potential mechanism underlying TET2 regulation of the CSE/H~2~S system in oxLDL-treated HUVECs, we performed studies to examine the impact of TET2 on methylation status of the CSE promoter. Bioinformatics analysis showed that the CSE promoter contained a CpG island which extended across 469 bp (**Figure [6A](#F6){ref-type="fig"}**), harboring a CG content of 61.6% with an observed-to-expected CpG ratio of 0.91, suggesting a well-defined CGI compared with the CpG island definition standard (**Table [1](#T1){ref-type="table"}**). These data of bioinformatics analyses suggest that the CSE promoter has the high probability to be modified by DNA methylation.

![Effects of TET2 on the methylation level of the CSE promoter in oxLDL-treated HUVECs. **(A)** The features of CpG Island in human CSE gene promoter region was analyzed using the UCSC Human Genome Browser (<http://genome.ucsc.edu/>). **(B)** A schematic diagram of the CpG dinucleotides within the CSE promoter. The nucleotide number is relative to the transcription start site of CSE. The red line indicates the region that was tested with BSP. **(C)** HUVECs were transfected with or without TET2 overexpression plasmid or TET2 shRNA plasmid in the presence of oxLDL for 24 h. The methylation levels of the CSE promoters in each group of cells were determined by BSP method. Each row represents an individual clone sequenced; black and white circles represent methylated and unmethylated CpGs sites, respectively. The number of methylated CpGs divided by the whole CpG sites examined is given as a percentage of methylation. **(D)** Immunostaining for 5hmC in each group of cells. 5hmC is red, DAPI staining is blue, *n* = 4. Scale bar = 20 μm.](fphar-08-00486-g006){#F6}

###### 

CpG island of cystathionine-γ-lyase (CSE) promoter region contrasted with the standard CpG island.

  Criteria           CGI definition Standard   CSE CGI
  ------------------ ------------------------- ---------
  DNA stretch (bp)   ≥200                      469
  GC content (%)     \>50%                     61.6
  Obs/Exp radio      \>0.6                     0.91

Obs/Exp radio, observed and expected ratio; CGI, CpG island.

Then, the methylation level of the CSE promoters in oxLDL-treated HUVECs with TET2 overexpression plasmid or TET2 shRNA plasmid was determined by BSP method. The region of the CpG dinucleotides within the CSE promoter tested with BSP was indicated by red line in **Figure [6B](#F6){ref-type="fig"}**. As shown in **Figure [6C](#F6){ref-type="fig"}**, the methylation level of the CSE promoter was 56.8% in HUVECs treated with oxLDL alone, but it was decreased up to 4% in oxLDL-treated HUVECs with TET2 overexpression and increased in oxLDL-treated HUVECs with the TET2 knockdown. 5hmC represents an intermediate product in the TET2 active DNA demethylation process. We also evaluated the impact of TET2 on the 5hmC level in these cells by immunostaining. As expected, the level of 5hmC was enhanced by TET2 overexpression plasmid and decreased by TET2 shRNA plasmid (**Figure [6D](#F6){ref-type="fig"}**).

Taken together, these results suggest that TET2 could upregulate CSE expression via DNA demethylation, resulting in an increased production of H~2~S in oxLDL-treated HUVECs.

Discussion
==========

In the present work, we confirmed that TET2 expression and the CSE/H~2~S system were downregulated by oxLDL in HUVECs. Furthermore, we found that TET2 can upregulate the CSE/H~2~S system and inhibit NF-κB activation, thus decrease the expressions of ICAM-1 and VCAM-1 and attenuate the adhesion of THP-1 cells to oxLDL-activated HUVECs. Notably, we demonstrated that TET2 increases CSE expression by promoting the demethylation of the CSE promoter in oxLDL-treated HUVECs. Taken together, our results showed a novel epigenetic pathway, by which TET2 upregulates the CSE/H~2~S system, leading to the protection of endothelial functions.

Oxidized low-density lipoprotein, an independent risk factor for atherosclerosis ([@B11]), plays a casual role in endothelial dysfunction ([@B30]). Our data showed that TET2 mRNA and protein expressions are reduced by oxLDL in concentration- and time-dependent fashion in HUVECs, which is consistent with the results from oxLDL-treated macrophages as we previously reported ([@B22]). It was reported that oxLDL downregulates the CSE/H~2~S system in THP-1 and Raw264.7 macrophages ([@B52]; [@B43]). We also demonstrated that oxLDL decreases the CSE expression and H~2~S production rate and level in concentration- and time-dependent manners in HUVECs. These data firstly confirm that TET2 level is positively correlated with CSE expression and H~2~S level in oxLDL-treated HUVECs.

The high expression of adhesion molecules, such as ICAM-1 and VCAM-1, leading to an abnormal increase in adhesion ability onto endothelial cell surface, is an important feature of endothelial dysfunction ([@B40]). It was confirmed that ICAM-1 is expressed in human atherosclerotic plaques. OxLDL can increase the expression of ICAM-1 on the endothelial cell surface ([@B32]; [@B37]; [@B49]). VCAM-1 is another important adhesion molecule in vascular endothelial cell surface, which can promote the adhesion of monocytes and T lymphocytes to endothelial cells ([@B13]). In this study, we found that TET2 overexpression reduced the expression of ICAM-1 and VCAM-1, and inhibited the adhesion THP-1 cells to oxLDL-activated HUVECs. However, TET2 silencing had opposite effects. Recent studies have shown that TET2 affects atherosclerosis progression. [@B9] found that TET2 knockout in macrophages aggravates inflammation and accelerates atherosclerosis in LDLR-/- mice. Our group previously reported that TET2 improves low shear stress induced-endothelial cell dysfunction ([@B48]), and inhibits atherosclerosis via upregulating autophagy activity and downregulating the expression of inflammation factors in ApoE-/- mice ([@B36]). Given that the oxLDL-induced endothelial dysfunction plays a critical role in atherosclerosis, our finding that TET2 can improve the endothelial dysfunction induced by oxLDL will further support an inhibitive effect of TET2 on atherosclerosis.

It is well known that the CSE/H~2~S system has a protective effect on endothelial cell functions ([@B34]; [@B12]; [@B38]; [@B45]; [@B53]; [@B19]). [@B34] and [@B12] have found that H~2~S decreases the ICAM-1 and VCAM-1 expressions in endothelial cells induced by TNF-α or high glucose and improves the endothelial dysfunction. We examined whether TET2 improvement of oxLDL-induced endothelial dysfunction was linked to the CSE/H~2~S system. Our results have illustrated that TET2 overexpression results in an enhanced expression of CSE mRNA and protein with an increase in H~2~S production rate and H~2~S levels in oxLDL-treated HUVECs. To our knowledge, this is the first report to demonstrate that TET2 upregulates the CSE/H~2~S system in HUVECs. Importantly, we have shown that the inhibitory effects of TET2 on the expressions of ICAM-1 and VCAM-1 and the adhesion of THP-1 cells to HUVECs were reversed when the CSE/H~2~S pathway was interrupted by CSE siRNA in oxLDL-treated HUVECs, suggesting a role for the CSE/H~2~S system in TET2 protection of endothelial functions.

Furthermore, we have shown that TET2 overexpression inhibited NF-κB activation in oxLDL-treated HUVECs, whereas the TET2 silencing had the opposing effects. It is known that NF-κB directly binds to the promoters of ICAM-1 and VCAM-1 genes and stimulates their gene expression ([@B15]; [@B28]; [@B2]). H~2~S is known to inhibit the activation of NF-κB in endothelial cells or macrophages in response to treatment with various stimuli ([@B33]; [@B44]; [@B34]; [@B12]). Therefore, it is conceivable that TET2 inhibits NF-κB activation through upregulating the CSE/H~2~S system, leading to a decrease in the expression of ICAM-1 and VCAM-1 in HUVECs. Indeed, the interference of the CSE/H~2~S pathway with CSE siRNA ameliorated the inhibitory effect of TET2 overexpression on NF-κB activation as shown in our results. In sum, our findings have suggested that the anti-atherosclerotic effect of TET2 may be mediated by the CSE/H~2~S system, but more *in vivo* studies will be required to establish the role of the TET2/CSE/H~2~S pathway in atherosclerosis.

DNA methylation and demethylation are two forms of epigenetic modifications. When located in a gene promoter, DNA methylation usually represses gene transcription, and DNA demethylation induces activation of gene transcription ([@B31]). TET2 effects are mediated by site-specific DNA demethylation through oxidizing 5mC into 5hmC, which is associated with gene transactivation in mammalian cells ([@B24]; [@B41]). TET2 has then emerged as a key activator of gene expression ([@B35]; [@B16]). As expected, TET2 overexpression increases, but TET2 knockdown reduces, the level of 5hmC in HUVECs. Our data have shown that CSE promoter region contains a well-defined CpG island, implicating its regulation by DNA methylation and demethylation ([@B51]). As expected, our results showed that the methylation level of CSE promoter was decreased by TET2 overexpression and increased by the TET2 knockdown in oxLDL-treated HUVECs. Supportively, the recent studies by [@B23] and [@B7] has shown that homocysteine or oxLDL-induced DNA hypermethylation of CpG-rich region in the CSE gene promoter contributes to the decrease of the CSE/H~2~S system in macrophages.

Conclusion
==========

This is the first report to show that TET2 improves oxLDL-induced endothelial dysfunction through the CSE/H~2~S/NF-κB pathway. Our data also revealed that TET2 promotes DNA demethylation of the CSE gene promoter, which may be the mechanism underlying TET2 up-regulation of the CSE/H~2~S system. Our findings not only provide a new perspective on the regulation of endogenous CSE/H~2~S system but also reveal a novel role for TET2 in the protection of endothelial functions, suggesting that TET2 may become a new drug target for treating atherosclerosis.
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Effects of CSE siRNA on the CSE/H~2~S system in oxLDL-treated HUVECs with TET2 overexpression. HUVECs were transfected with or without TET2 overexpression plasmid or TET2 overexpression plasmid + CSE siRNA in the presence of oxLDL for 24 h. The expression of CSE protein **(A)** was examined via western blot analysis in cells. **(B)** The H~2~S production rates in each group of cells were determined as described in "Materials and Methods" section. **(C)** Representative fluorescent images of intracellular H~2~S level detection in each group of cells using H~2~S-specific fluorescent probes. Scale bar = 20 μm. All results are expressed as the mean ± SD of three independent experiments. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. oxLDL-treated alone group. ^\#\#^*P* \< 0.01 vs. TET2 overexpression plasmid-treated group.
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